Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
🚫 GENESIS SOLD OUT
DAPAPAY COMING

Business

Trump Expands TrumpRx Program Offering Discounts on More Than 800 Medications

Published

on

TrumpRx Launches: President Trump Unveils Discounted Drugs Website

President Donald Trump announced Friday an expansion of the TrumpRx.gov program, adding 160 more prescription drugs and bringing the total number of discounted medications available to more than 800.

The initiative, launched earlier this year, aims to provide cash-paying consumers with transparent pricing and savings on commonly used drugs by bypassing traditional insurance middlemen. Trump highlighted the expansion in a Truth Social post, stating it now covers four out of five prescriptions filled by Americans.

“I am pleased to announce that TrumpRx.gov is adding another 160 Prescription Drugs, at highly discounted prices, for a new total of over 800 of the most commonly-used Prescription Drugs,” Trump wrote. “TrumpRx.gov will now provide clear, transparent, and DISCOUNTED offerings for FOUR OUT OF FIVE of every prescription filled by Americans.”

The program builds on agreements with major pharmaceutical companies under a “most-favored-nation” pricing approach. Participating drugmakers received certain tariff exemptions in exchange for lowering prices on selected medications and extending discounts to eligible consumers. Companies including Eli Lilly and Novo Nordisk have joined, offering reductions on popular GLP-1 weight-loss and diabetes treatments.

Advertisement

Discounted medications now include inhalers, HIV treatments, diabetes drugs, fertility medications and a wide range of generics. The website allows users to search for specific drugs, view estimated savings compared to insurance co-pays and generate coupons redeemable at participating pharmacies or directly through manufacturers.

Trump credited the program with already delivering significant savings. “These Most Favored Nations Deals have already, in fact, saved American Patients over 400 Million Dollars since the launch of TrumpRx.gov,” he said. He tied the success to broader trade policies, noting tariffs helped secure favorable terms.

The initiative reflects ongoing efforts to address high prescription drug costs in the United States, where prices for many medications exceed those in other developed countries. Trump positioned the expansion as a continuation of first-term achievements while pursuing more aggressive reductions.

“I was proud to make History during my First Term when we lowered Drug Prices, even if by a tiny percentage, because this amounted to a HUGE change compared to other presidents only raising Drug Prices, endlessly and significantly, every year,” Trump wrote. “Then, during my Second Term, I decided to go BIG with Most Favored Nations Pricing.”

Advertisement

Administration officials, including Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz, have encouraged Americans to compare prices on TrumpRx.gov before filling prescriptions. The platform integrates data from partners such as Amazon Pharmacy, Mark Cuban’s Cost Plus Drugs and GoodRx, providing multiple options for cash-paying patients.

The program targets uninsured individuals or those whose insurance co-pays exceed available cash prices. Users must typically pay out-of-pocket and forgo insurance reimbursement for the discounted medications. This approach aims to increase price transparency and competition in the pharmaceutical market.

Critics have questioned the scale of impact, noting that while the program covers hundreds of drugs, it represents a fraction of the thousands of FDA-approved medications. Some independent analyses suggest overlapping discounts with existing platforms, though the administration maintains the most-favored-nation deals deliver unique savings on key treatments.

Supporters highlight specific examples, such as substantial reductions on weight-loss medications like Ozempic, dropping from over $1,000 to around $200 monthly in some cases. The program also covers chronic condition treatments that impose heavy burdens on patients.

Advertisement

The expansion comes amid broader health care policy discussions. Trump has directed the administration to pursue additional partnerships and deals to further lower prices. Officials continue negotiating with more drugmakers to expand the catalog.

Pharmaceutical industry reactions have been mixed. Participating companies point to increased volume from cash buyers offsetting lower per-unit prices, while others express concerns about tariff linkages and long-term pricing pressures. Patient advocacy groups welcome any relief on costs but call for more comprehensive reforms addressing insurance and generic access.

TrumpRx.gov launched in February 2026 with an initial set of brand-name drugs. The May addition of hundreds of generics marked a significant broadening, followed by this latest update. The site has seen growing traffic as awareness spreads through administration promotions and word-of-mouth savings reports.

Health policy experts note the program’s focus on cash prices fills a gap for the uninsured and underinsured but does not directly lower costs within insurance plans. Its success depends on consumer adoption and continued manufacturer participation.

Advertisement

The initiative ties into larger administration goals of reducing overall health care spending through competition and international price benchmarking. Trump has repeatedly emphasized that Americans should not pay more than citizens in other nations for the same drugs.

As the program grows, questions remain about sustainability and potential effects on innovation and drug development. Proponents argue that volume increases and efficiency gains can balance lower margins, while skeptics worry about supply chain impacts or reduced research investment.

For consumers, the practical benefit lies in easy access to price comparisons. A quick search on TrumpRx.gov can reveal options that beat insurance co-pays, potentially saving hundreds or thousands annually for those managing chronic conditions.

The White House continues promoting the site through public events and digital campaigns. With midterm considerations and ongoing health care debates, the expansion serves as a tangible deliverable on promises to tackle drug prices head-on.

Advertisement

Looking ahead, further additions to the program are expected as more deals materialize. Administration officials have signaled openness to expanding eligibility and integrating additional pharmacy partners. The goal remains providing meaningful relief to American patients facing high out-of-pocket costs.

TrumpRx represents one piece of a multifaceted approach to pharmaceutical pricing. Combined with other policy tools, it aims to shift dynamics in a market long criticized for opacity and high costs. As usage data accumulates, its real-world impact will become clearer.

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

White House AI policy adviser Krishnan to leave position, the Information reports

Published

on

White House AI policy adviser Krishnan to leave position, the Information reports


White House AI policy adviser Krishnan to leave position, the Information reports

Continue Reading

Business

Deferring jet orders over Iran war would be costly for Middle Eastern carriers, IATA VP says

Published

on

Deferring jet orders over Iran war would be costly for Middle Eastern carriers, IATA VP says


Deferring jet orders over Iran war would be costly for Middle Eastern carriers, IATA VP says

Continue Reading

Business

Air New Zealand plans for elevated fuel costs into 2027

Published

on

Air New Zealand plans for elevated fuel costs into 2027


Air New Zealand plans for elevated fuel costs into 2027

Continue Reading

Business

Elon Musk to attend ASML tech conference to talk Terafab – Bloomberg

Published

on


Elon Musk to attend ASML tech conference to talk Terafab – Bloomberg

Continue Reading

Business

Israeli strike in Gaza kills seven people, including two women, medics say

Published

on

Israeli strike in Gaza kills seven people, including two women, medics say


Israeli strike in Gaza kills seven people, including two women, medics say

Continue Reading

Business

Oracle: Next Level Up (NYSE:ORCL)

Published

on

Oracle: Next Level Up (NYSE:ORCL)

This article was written by

Stone Fox Capital is an RIA from Oklahoma. Mark Holder is a CPA with degrees in Accounting and Finance. He is also Series 65 licensed and has 30 years of investing experience, including 15 years as a portfolio manager. Mark leads the investing group Out Fox The Street where he shares stock picks and deep research to help readers uncover potential multibaggers while managing portfolio risk via diversification. Features include various model portfolios, stock picks with identifiable catalysts, daily updates, real-time alerts, and access to community chat and direct chat with Mark for questions. Learn more.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ORCL over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock, you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.

Advertisement

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Continue Reading

Business

Finnair explores Starlink, Amazon for inflight Wi-Fi upgrade – Bloomberg

Published

on


Finnair explores Starlink, Amazon for inflight Wi-Fi upgrade – Bloomberg

Continue Reading

Business

Charles Barkley Urges LeBron James to Return to Cleveland for Final Chapter

Published

on

Lebron James Post Game Interview: LeBron James Leads Lakers

Charles Barkley has a clear message for LeBron James as the NBA superstar weighs his future: Go back to Cleveland.

The Hall of Famer and TNT analyst made the comments on ESPN’s “Get Up” on Friday, June 5, arguing it is James’ only logical move as he enters free agency following the Los Angeles Lakers’ playoff exit.

“LeBron only has one play and that’s to go back to Cleveland,” Barkley said. “That’s his only smart and logical choice.”

James, 41, became an unrestricted free agent after declining his player option with the Lakers. The four-time NBA champion has yet to announce his plans for the 2026-27 season or whether he will return for a 24th campaign. He has said his decision would come after family time, with no firm timeline set beyond late June or July.

Advertisement

Barkley believes James should never have left Cleveland after the 2017-18 season. A return, he said, would position the Cavaliers as Eastern Conference favorites or at least strong contenders.

“They’ll probably be the favorites in the East or in that conversation,” Barkley added.

The Lakers were swept 4-0 by the top-seeded Oklahoma City Thunder in the Western Conference semifinals. Oklahoma City won the series-clinching Game 4 by 115-110 on May 11, completing a dominant run while remaining unbeaten through the early playoffs. James showed flashes of his elite form but could not overcome the youth and depth of the Thunder.

Barkley argued that staying in Los Angeles would not make competitive sense.

Advertisement

“They are not going to be competitive,” he said of the Lakers. “If he stays in L.A., he is doing it for off-the-court reasons.”

He suggested the franchise should shift focus to building around Luka Doncic, acquired in a prior blockbuster deal.

Barkley also dismissed the idea of James joining another team purely to chase a fifth title and catch Michael Jordan’s six championships.

“If he goes to any other teams, it would just be like him trying to win championships to catch Michael Jordan. It wouldn’t make sense. He can’t catch Michael Jordan as a mercenary in my opinion.”

Advertisement

James has won titles with three franchises: two with the Miami Heat in 2012 and 2013, one with the Cleveland Cavaliers in 2016 that ended a 52-year championship drought for the city, and one with the Lakers in 2020 during the bubble season. That versatility remains a hallmark of his career.

The latest comments from Barkley add fuel to ongoing speculation about James’ next move. Cleveland has long been viewed as a sentimental favorite for a homecoming, especially given James’ Akron roots and the emotional connections forged during his first two stints with the Cavaliers.

Recent social media activity, including James liking an Instagram post urging him to “come home,” has intensified rumors. However, financial hurdles remain for Cleveland to create enough cap space or use exceptions effectively for a veteran of James’ stature.

For the Lakers, the offseason brings critical questions. The team has expressed desire to retain James, but the sweep highlighted roster shortcomings despite the presence of Doncic and supporting pieces. Reports indicate the front office must demonstrate a clear plan to improve competitiveness before James commits.

Advertisement

James addressed his mindset in mid-May on his “Mind the Game” podcast with Steve Nash.

“Obviously, I understand that I’m a free agent and I can control my own destiny … but like, I haven’t even really got to that point,” James said. “I haven’t even taken my family vacation yet. That’s kind of the thing at the forefront of my mind.”

Memorial Day has passed, yet public comments from James and his camp have remained minimal. His decision will ripple across the league, influencing free agency for multiple teams with cap flexibility or interest in a high-profile veteran.

Other potential suitors have surfaced in speculation, including the Golden State Warriors, who could pair James with Stephen Curry in a star-studded but aging lineup. Knicks and other Eastern Conference teams have also been mentioned, though Barkley’s point about non-Cleveland moves feeling mercenary resonates with some observers.

Advertisement

James averaged strong numbers in the 2025-26 regular season, leading the league in fast-break points while posting around 20.9 points, 6.1 rebounds and 7.2 assists per game across roughly 60 contests. In the playoffs, he delivered moments reminiscent of his prime, but age and supporting cast limitations showed against Oklahoma City’s speed and versatility.

A return to Cleveland would offer narrative symmetry. James delivered the city’s first major sports title in generations in 2016 before departing for Los Angeles in 2018. Fans and former teammates have welcomed the idea of a farewell tour in The Land.

Yet basketball decisions involve more than sentiment. Cleveland’s young core, led by Donovan Mitchell and others, showed promise but faced questions about locker room dynamics and playoff readiness. Adding James could elevate them immediately while providing mentorship.

For James personally, priorities include family, legacy and sustained competitiveness. At 41, he has defied Father Time longer than most, but the physical demands of an 82-game season plus playoffs remain significant.

Advertisement

League-wide, the NBA continues evolving with younger stars and superteams. The Thunder’s ascent as defending champions underscores the premium on youth, depth and two-way play — areas where a veteran like James can still contribute as a facilitator and closer but no longer as the undisputed alpha every night.

Analysts note that James’ opt-out creates flexibility for all parties. The Lakers hold Bird rights and can offer the most money, but James has leverage to explore options or even retirement, though the latter seems unlikely given his competitive drive and recent production.

Barkley’s outspoken style has made him a fan favorite, and his comments on James carry weight from one generational talent to another. The two have shared candid exchanges over the years, with Barkley often praising James’ greatness while offering blunt career advice.

Cleveland Cavaliers fans have embraced the possibility. Social media and local reports reflect excitement at the prospect of James closing his career where it began, potentially boosting ticket sales and community engagement.

Advertisement

However, NBA free agency is notoriously unpredictable. Teams must balance short-term contention with long-term salary cap management. James’ eventual choice — whether Cleveland, Los Angeles, elsewhere or retirement — will set the tone for the summer.

As of early June 2026, silence from James’ camp persists. League insiders expect movement closer to the draft and official free agency window in July, though his timeline could extend.

Barkley’s recommendation boils down to legacy and logic: Finish where it started, in front of the fans who have cheered the highs and lows of his journey.

James has never shied from tough decisions. From “The Decision” in 2010 to the 2014 homecoming and the 2018 move west, each choice reshaped his career and the league.

Advertisement

Whether he heeds Barkley’s call remains to be seen. For now, the basketball world waits, pondering one of the most anticipated free agency chapters in recent NBA history.

The coming weeks will clarify if Cleveland gets its hero’s return, if Los Angeles builds a new chapter with its aging star, or if another twist awaits in LeBron James’ remarkable story.

Continue Reading

Business

FDA grants orphan drug status for Merck’s pembrolizumab in NEPC

Published

on


FDA grants orphan drug status for Merck’s pembrolizumab in NEPC

Continue Reading

Business

Frasers Group eyes Metrocentre bid amid property expansion – Sky News

Published

on


Frasers Group eyes Metrocentre bid amid property expansion – Sky News

Continue Reading

Trending

Copyright © 2025